Nektar Therapeutics Names Rubinstein New Interim CFO

Dow Jones05-09

By Kelly Cloonan

Nektar Therapeutics named Linda Rubinstein as its next interim chief financial officer, effective May 15.

Rubinstein, a partner of CFO services firm FLG Partners, succeeds Sandra Gardiner, who was also CFO on an interim basis and is a partner at FLG, according to a Friday filing with the Securities and Exchange Commission.

Gardiner will be retiring and stepping down from the position at Nektar, which she has held since 2023, Nektar said.

Rubinstein has been permanent and interim CFO of several public and private companies including Adverum Biotechnologies, Diasome, Five Prime, Ingenuity, iPierian, Kezar, and Tunitas.

Gardiner will continue to support the transition as necessary, Nektar said.

Nektar also said it entered an amendment to its consulting agreement with FLG, under which it will pay FLG $650 per hour for Rubinstein's services.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 08, 2026 18:20 ET (22:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634295460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 06:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634295460","market":"us","top_or_hot":-1,"title":"Nektar Therapeutics Names Rubinstein New Interim CFO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> named Linda Rubinstein as its next interim chief financial officer, effective May 15. \n</p>\n<p>\n  Rubinstein, a partner of CFO services firm FLG Partners, succeeds Sandra Gardiner, who was also CFO on an interim basis and is a partner at FLG, according to a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Gardiner will be retiring and stepping down from the position at Nektar, which she has held since 2023, Nektar said. \n</p>\n<p>\n  Rubinstein has been permanent and interim CFO of several public and private companies including <a href=\"https://laohu8.com/S/ADVM\">Adverum Biotechnologies</a>, Diasome, <a href=\"https://laohu8.com/S/FPRX\">Five Prime</a>, Ingenuity, iPierian, Kezar, and Tunitas. \n</p>\n<p>\n  Gardiner will continue to support the transition as necessary, Nektar said. \n</p>\n<p>\n  Nektar also said it entered an amendment to its consulting agreement with FLG, under which it will pay FLG $650 per hour for Rubinstein's services. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 18:20 ET (22:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics Names Rubinstein New Interim CFO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics Names Rubinstein New Interim CFO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 06:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> named Linda Rubinstein as its next interim chief financial officer, effective May 15. \n</p>\n<p>\n  Rubinstein, a partner of CFO services firm FLG Partners, succeeds Sandra Gardiner, who was also CFO on an interim basis and is a partner at FLG, according to a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Gardiner will be retiring and stepping down from the position at Nektar, which she has held since 2023, Nektar said. \n</p>\n<p>\n  Rubinstein has been permanent and interim CFO of several public and private companies including <a href=\"https://laohu8.com/S/ADVM\">Adverum Biotechnologies</a>, Diasome, <a href=\"https://laohu8.com/S/FPRX\">Five Prime</a>, Ingenuity, iPierian, Kezar, and Tunitas. \n</p>\n<p>\n  Gardiner will continue to support the transition as necessary, Nektar said. \n</p>\n<p>\n  Nektar also said it entered an amendment to its consulting agreement with FLG, under which it will pay FLG $650 per hour for Rubinstein's services. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 18:20 ET (22:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634295460","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634295460","pubTimestamp":1778278800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nektar Therapeutics named Linda Rubinstein as its next interim chief financial officer, effective May 15.Rubinstein, a partner of CFO services firm FLG Partners, succeeds Sandra Gardiner, who was also CFO on an interim basis and is a partner at FLG, according to a Friday filing with the Securities and Exchange Commission.Gardiner will be retiring and stepping down from the position at Nektar, which she has held since 2023, Nektar said.Rubinstein has been permanent and interim CFO of several public and private companies including Adverum Biotechnologies, Diasome, Five Prime, Ingenuity, iPierian, Kezar, and Tunitas.Nektar also said it entered an amendment to its consulting agreement with FLG, under which it will pay FLG $650 per hour for Rubinstein's services.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"Nektar Therapeutics任命Rubinstein为新任临时首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Nektar Therapeutics named Linda Rubinstein as its next interim chief financial officer, effective May 15. \n\n\n  Rubinstein, a partner of CFO services firm FLG Partners, succeeds Sandra Gardiner, who was also CFO on an interim basis and is a partner at FLG, according to a Friday filing with the Securities and Exchange Commission. \n\n\n  Gardiner will be retiring and stepping down from the position at Nektar, which she has held since 2023, Nektar said. \n\n\n  Rubinstein has been permanent and interim CFO of several public and private companies including Adverum Biotechnologies, Diasome, Five Prime, Ingenuity, iPierian, Kezar, and Tunitas. \n\n\n  Gardiner will continue to support the transition as necessary, Nektar said. \n\n\n  Nektar also said it entered an amendment to its consulting agreement with FLG, under which it will pay FLG $650 per hour for Rubinstein's services. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 18:20 ET (22:20 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634295460","isCrawlerRequest":true}